Cumulative Troponin T Release after Acute Myocardial Infarction. Influence of Reperfusion by Kragten, Johannes A. et al.
Eur J Clin Chem Clin Biochem 1997; 35(6):459-467 © 1997 by Walter de Gruyter · Berlin · New York
Cumulative Troponin T Release after Acute Myocardial Infarction,
Influence of Reperfusion
Johannes A. Kragten1, Wim Th. Hermens2 and Mar ja P. van Dieijen-Visser3
1
 Department of Cardiology, Hospital DeWever and Gregorius, Heerlen, The Netherlands
2
 Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands
3
 Department of Clinical Chemistry, Academic Hospital, Maastricht, The Netherlands
Summary: For troponin T a characteristic biphasic change in the plasma time-concentration curve has been de-
scribed, especially in patients with early reperfusion after thrombolytic therapy. As troponin T is bound to myofibril-
lar structures, treatment strategy or treatment outcome could influence the cumulative plasma release of this protein
in a different way compared to the cumulative release of free cytoplasmic cardiac enzymes.
The present study is the first study comparing the total quantity of troponin T released by the heart during the first
168 hours after acute myocardial infarction, both in patients treated with thrombolytic therapy (n = 16) and in
patients not treated with thrombolytic therapy (n = 7). On the basis of clinical symptoms and coronary arteriogram
within 24 hours, the patients treated with thrombolytic therapy were divided into two groups, reperfused (n = 9)
and non-reperfused (n = 7). In the patients not treated with thrombolytic therapy, absence of spontaneous early
reperfusion was judged only from clinical symptoms.
Cumulative troponin T release into plasma was compared to the cumulative release of the cytoplasmic cardiac
enzymes creatine kinase (EC 2.7.3.2) and hydroxybutyrate dehydrogenase (EC 1.1.1.27). Cumulative release, i.e.,
infarct size, was calculated using a two-compartment model for circulating proteins. Mean tissue contents, per gram
wet weight, of 156 U/g for hydroxybutyrate dehydrogenase, 2.163 U/g for creatine kinase and 234 g/g for troponin
T, were used to express infarct size in gram-equivalents of healthy myocardium per litre plasma (g-eq/1).
Release rates were represented by the ratio of cumulative quantities released in 10 hours and 72 hours for creatine
kinase and hydroxybutyrate dehydrogenase and in 10 hours and 168 hours for troponin T.
Conclusions
— Plasma time-concentration curves and release rates of troponin T in patients treated with thrombolytic therapy
showing reperfusion differ significantly from those of patients not treated with thrombolytic therapy, showing
no reperfusion.
— Creatine kinase and hydroxybutyrate dehydrogenase release is completed within 72—100 hours in all patients,
whereas troponin T release still continues after 168 hours.
— Cumulative troponin T release at 168 hours is only a fraction (around 8%) of cumulative cytoplasmic enzyme
release and the percentage released is not influenced by the treatment strategy or outcome, i. e., vessel patency.
— Although troponin T release is only a fraction of the cumulative enzyme release (infarct size) there is a highly
significant correlation between both, independent of the treatment strategy or treatment outcome.
Introduction
During acute myocardial infarction, failure to unblock the occurrence of reperfusion arrhythmias and the reso-
the infarct-related vessel is associated with poor out- lution of infarct-related chest pain (4). Predictability of
come and prognosis. It is evident from both laboratory reperfusion proved to be clearly insufficient in several
and clinical studies that the benefits of thrombolytic trials using these criteria (5). To date, reliable determina-
therapy are conferred by restoration of patency of the tion of reperfusion is only possible by coronary angio-
infarct-related artery (1—3). The success of reperfusion graphy. However, acute routine angiography in all pa-
therapy is commonly assessed by the normalization of tients receiving thrombolytic therapy is impractical or
segment T elevation in the surface electrocardiogram, unavailable in an emergency setting and may eventually
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cause harm to some patients. Hence, reliable methods
other than angiography are needed to detect coronary
reperfusion early during the hospital course. A single
non-invasive marker to evaluate reperfusion would be
of significant clinical benefit. The ideal application
would be the use of a simple serum test as an early
non-invasive method to assess successful reperfusion.
For troponin T it has been suggested in several studies
that the effects of reperfusion on the troponin T plasma
time-concentration curves in acute myocardial infarction
can be used to non-invasively assess the effectiveness of
thrombolytic therapy (6—15). A characteristic biphasic
change in plasma concentration has been described, es-
pecially in patients with early reperfusion after thrombo-
lytic therapy (6. 16, 17). Intracellular compartmentation
of troponin T, i. e. the presence of both free cytosolic
and structurally bound troponin T, seems the primary
cause of this biphasic troponin T release into plasma (6,
16, 18). In fresh cardiac tissue the free cytosolic tro-
ponin T fraction is about 4—6% of the total troponin T
content in cardiac tissue (6, 19). The structurally bound
troponin T has to be dissociated from the contractile
myofibrillar structures before it can be released into the
circulation and is therefore more slowly released into
plasma compared to the free cytosolic fraction, resulting
in a biphasic time-concentration curve. In the isolated
perfused rat heart it was demonstrated that prolonged
ischemia induces a continuous liberation of cardiac
troponin T, most probably from disintegrating myofi-
bres, whereas membrane damage leads almost exclu-
sively to leakage of the functionally unbound troponin
T pool. These findings may explain the biphasic serum
concentration changes of cardiac troponin T in patients
showing reperfusion after acute myocardial infarction
(18).
In a recent study, in patients treated with thrombolytic
therapy, we found that the total plasma release of tro-
ponin T after 72 hours is about 5% and after 168 hours
about 8% of the total recovery of the cytoplasmic
cardiac enzymes creatine kinase and hydroxybutyrate
dehydrogenase after 72 hours (19). Cumulative release
was expressed in gram equivalents of healthy heart mus-
cle per litre plasma, i. e. infarct size (20, 21).
The aim of the present study is to investigate the cumu-
lative release of troponin T in different patient groups.
As troponin T is bound to myofibrillar structures, pres-
ence or absence of reperfusion within 24 hours might
influence the total release of this protein in a different
way compared to total plasma release of the free cyto-
solic cardiac markers. Therefore, the timed cumulative
troponin T release pattern has been compared with the
cumulative release patterns of the cytoplasmic cardiac
enzymes creatine kinase and hydroxybutyrate dehydro-
genase in patients treated with thrombolytic therapy,
both reperfused and non-reperfused and in patients not
receiving thrombolytic therapy.
Patients and Methods
Patients
Patients (12 men and 11 women) presented at the Department of
Cardiology of the Hospital DeWever en Gregorius in Heerlen with
chest pain and segment T elevation typical of acute myocardial
infarction within 6 hours after the onset of symptoms were in-
cluded in this study.
From these patients 16 (11 men and 5 women) were treated with
thrombolytic therapy. First 160 mg of acetylosalicylic acid (aspirin)
were given (unless already given by general practitioner or ambu-
lance nurses), followed by thrombolytic therapy, which consisted
of 1.5 million units of streptokinase, given by infusion in 40 min.
Four hours after starting thrombolytic therapy heparin was given,
12 500 units subcutaneously, every 12 h, for 5 days.
On the basis of clinical symptoms and coronary arteriograms
within 24 h, the patients treated with thrombolytic therapy, strepto-
kinase (S), were divided into two groups, reperfused (n = 9, group
S+R+) and non-reperfused (n = 7, group S+R~) patients. The third
group (group S~) consisted of seven patients (6 women and 1 man)
not treated with thrombolytic therapy. In this group no coronary
arteriograms were performed and the absence of reperfusion was
judged from clinical symptoms only.
All patients included in the study had given informed consent. Ex-
cluded were patients with increased risk of bleeding, previous coro-
nary bypass surgery or Q-wave infarction in the same location,
severe hepatic or renal disease, or inability to give informed con-
sent.
Venous blood samples of 10 ml were obtained just before starting
thrombolytic therapy and 1, 2, 3, 4, 5, 6, 8, 10, 14, 18, 22, 28, 34,
46, 58, 70, 82, 94, 118, 142, 166 hours later. Exact sampling times
were recorded and expressed as time after the onset of symptoms.
Most samples were taken from indwelling catheters and care was
taken to prevent haemolysis. Contamination with infused solutions
was prevented by using a second catheter for infusion purposes.
Blood was collected in pre-distributed and labelled tubes, contain-
ing dry heparin to prevent clotting and was taken to the laboratory
immediately. Plasma samples, obtained after routine centrifugation,
were stored at —70 °C until analysis. All procedures followed were
approved by the Medical Ethical Committee of the Hospital. Pa-
tient data for the three groups are presented in table 1.
Enzyme and troponin T assays
Creatine kinase and hydroxybutyrate dehydrogenase
Enzymatic activities of creatine kinase and hydroxybutyrate dehy-
drogenase were measured spectrophotometrically at 37 °C using a
centrifugal analyzer (Cobas Bio System, Hoffmann La Roche, Ba-
sel, Switzerland). Commercially available test kits were used for
creatine kinase-N-acetylcysteine (International Federation of Clin-
ical Chemistry [IFCC] recommendation, Unimate 3 Roche, art no.
07 3647 3) and hydroxybutyrate dehydrogenase (Deutsche Gesell-
schaft fur Klinische Chemie [DGKC] recommendation, optimized
test from Boehringer, art no. 1442 589). The hydroxybutyrate de-
hydrogenase test is based on preferential catalytic activity of the
myocardial isoforms LDH! and LDH2 of lactate dehydrogenase
in the conversion of ct-ketobutyrate. Activities were expressed in
micromoles of substrate converted per minute (U), either per litre
of plasma (U/l) or per gram wet weight of tissue (U/g).
Troponin T
Troponin T was measured using the troponin T immunoassay from
Boehringer Mannheim (22). The assay was carried out in coated
tubes, using the Boehringer Mannheim ES22 photometer.
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Cumulative release of enzymes and troponin T
into plasma
Q(i), the cumulative release of enzyme activity and troponin T con-
centration per litre of plasma from the onset of acute myocardial in-
farction (t = 0) up to time t, was calculated with the following ex-
pression for a two-compartment model for circulating proteins:
Q(0 = C(0 + TER J exp{- ERR(f - τ)} C(t)d τ + FCR J C(i)dT.
ο ο
The three terms are the enzyme activity in plasma, the extravasated
activity and the activity eliminated from plasma, all three expressed
per litre of plasma. The parameters TER, ERR and FCR represent
the fractional rate constants for transcapillary escape, extravascular
return and fractional catabolism, respectively. This two-compart-
ment model has been validated in the dog (21, 23, 24) and parame-
ter values estimated in man are (20):
FCRHBDH = 0.015 IT1, FCRcK = 0.20 rT1,
TER = 0.014 hr1 and ERR = 0.018 h~'.
For troponin T, a value of FCR = 0.11 ± 0.05 h"1 (mean ± SD)
was obtained from a fitting procedure on troponin T and hydroxy-
butyrate dehydrogenase plasma curves, as described by Willems et
al. (19, 20). The procedure is based on simultaneous release of the
two proteins from the same (cytoplasmic) compartment, that is, the
released troponin T should be the free cytosolic fraction. Therefore
fitting was limited to the first 24 hours after first symptoms and it
was verified that fitting over 18 or 30 hours gave similar results,
which indicates that the release of fibrillar troponin T remains neg-
ligible during this period. The mean obtained value of FCR^-opo,,^
 T
= 0.11 h"1 was used in the calculations (19). The calculations are
not influenced by the plasma release rates. Knowledge of the clear-
ance and extravasation rates of proteins once entered into the circu-
lation are sufficient for calculation of the cumulative release into
the plasma compartment (25). The two pools used in the two-com-
partment model are the intra- and extravascular pool and not the
free and bound proteins. So with the two-compartment model for
circulating proteins, the amount of protein entering the circulation
can be calculated. The model has been extensively verified both in
animal and in experimental studies (20, 25—27).
Plasma enzyme activities measured at time t, C(f), were corrected
by subtraction of the normal steady state activities Cs. If the first
plasma sample was obtained within 4 hours after the onset of
symptoms, the corresponding enzyme activities were used for Cs.
In the remaining cases, fixed mean values of 100 U/l, 112 U/l and
0 μg/l were used for creatine kinase, hydroxybutyrate dehydroge-
nase and troponin T, respectively.
Infarct size in g-eq of tissue per litre of plasma
In order to express myocardial injury in g-eq of healthy myocar-
dium per litre of plasma, the cumulative release of enzyme per litre
of plasma was divided by the respective enzyme content per gram
wet weight of cadiac tissue. For creatine kinase 2163 U/g wet
weight, for hydroxybutyrate dehydrogenase 156 U/g and for tro-
ponin T 234 μg/g were used (19, 28).
Statistical analysis
The release curves of proteins into plasma are presented as means
with standard error of the mean. Pearsons correlation coefficient
was calculated to show relations between cumulative enzyme and
troponin T release. The Mann Whitney U-test was used for non-
parametric comparison of data of two independent groups. The
level of significance was set at p < 0.05.
Results
Mean plasma concentration after acute
myocardial infarction
Mean plasma troponin T concentrations and creatine
kinase and hydroxybutyrate dehydrogenase activities
as a function of time after the onset of symptoms in
the three patient groups are shown respectively in the
figures la,b,c. At the right side of each figure an
enlargement of the plasma release curves during the
first 10 hours is given. Differences in time from onset
of symptoms to peak are most significant between
patients treated with thrombolytic therapy without re-
periusion (group S+R~) compared to patients not
treated with thrombolytic therapy, showing no reperfu-
sion (S~), see table 1.
The biphasic troponin T curve clearly indicates a second
source of release, starting about 40 hours after the onset
of symptoms. The biphasic troponin T release is more
clear in patients treated with thrombolytic therapy com-
pared to patients not treated with thrombolytic therapy.
In patients not treated with thrombolytic therapy, show-
ing no reperfusion, delayed time to peak values were
found for all cardiac markers studied and for troponin
T the ratio of plasma troponin T a t l 6 h t o 3 6 h was
significantly lower in the non-treated non-reperfused pa-
tients (tab. 1).
Cumulative release of enzymes into plasma
For troponin T, creatine kinase and hydroxybutyrate de-
hydrogenase, the time versus cumulative release, ex-
pressed in gramequivalents of tissue per litre of plasma,
is shown respectively in the figures 2a, b and c. At the
right side of each figure an enlargement of the cumula-
tive release during the first 10 hours is given. Figure 2
and table 1 show that the cumulatively released quanti-
ties of creatine kinase and hydroxybutyrate dehydroge-
nase amount to approximately similar estimates of the
extent of injury, i.e., infarct size after 72 to 100 hours.
Cumulative troponin T release is still increasing after
168 hours and is only a fraction of cumulative enzyme
release.
Cumulative release of troponin T into plasma
After 168 hours the mean troponin T release, expressed
as a percentage of the cumulative enzyme release, is
comparable between the groups and is only 6.6 to 8.7%
of the cumulative enzyme release after 72 hours (tab. 1).
Figure 2a shows that troponin T release still continues
after 168 hours, whereas the release of creatine kinase
and hydroxybutyrate dehydrogenase is already com-
pleted after 72-100 hours.
Correlation between infarct size calculated
with different cardiac markers
Figure 3 shows that although the mean total release of
troponin T after 72 hours is only a fraction of the mean
total release observed for hydroxybutyrate dehydroge-
nase after 72 hours, a highly significant correlation is
observed between cumulative hydroxybutyrate dehydro-
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gen se release and cumulative troponin T after 168
hours for all three groups. Slope and intercept of the
regression lines are comparable, indicating that the total
cumulative release of troponin T is not influenced by
treatment strategy or outcome.
Figure 3 shows that the percentage troponin T released
is not influenced by infarct size.
Discussion
Patient groups
Since the introduction of thrombolysis this therapy has
proven to be very effective in patients suffering from
acute myocardial infarction. For that reason every pa-
tient with signs of acute myocardial infarction will be
stratified for thrombolysis, unless there is a significant
contraindication. Mostly these contraindications are:
time passed since the onset of symptoms (i. e. > 6—9
hours), a history of recent cerebrovascular accident or a
history of gastro-intestinal bleeding or ulcer. It goes
without saying that these factors influence the composi-
tion of the two different groups, so that it is very difficult
to include a group of patients receiving no thrombolytic
therapy that matches the other group. In the present study
treatment delay was comparable between the groups.
As we primarily investigated differences in cumulative
release between the groups, clinical symptoms and coro-
nary arteriograms within 24 hours were sufficient to de-
termine vessel patency. Patients with completely dif-
ferent vessel patency were present and therefore a pos-
sible influence of vessel patency on the cumulative re-
lease of troponin T could be investigated by comparing
cumulative enzyme and cumulative troponin T release;
especially since it is known that cumulative enzyme re-
lease, i. e. enzymatic infarct size, is not influenced by
vessel patency (29). Van der Laarse showed that the re-
lation between enzymatic infarct size assessed from cu-
mulative hydroxybutyrate dehydrogenase release and
left ventricular performance was not influenced by the
presence or absence of reperfusion (29).
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Fig. la—c Mean plasma concentrations of troponin Τ Χ 100 in
micrograms per litre (a) and of creatine kinase (b) and hydroxybu-
tyrate dehydrogenase (c) expressed in U/l, in patients treated with
thrombolytic therapy, with reperfusion (A, S+R+, η = 9) or with-
out reperfusion (·, S+R , η = 7) and in patients not treated with
thrombolytic therapy and showing no reperfusion (o, S~, n = 7).
Upper standard error of the mean is indicated.
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Tab. 1 Patient data
Patient group S+R
9)
Mean ± SD
Treatment delay [h]
Age [years]
Time peak CK [h]
Time peak HBDH [h]
Time peak troponin T [h]
Troponin T at 16 h/troponin T at 36 h
QHBDH (72) [g-eq/1]
QCK (72) [g-eq/1]
QtroponinT(72)[g-eq/l]
Qtroponin τ (168) [g-eq/1]
QtroponinT (168)/QHBDH (72) X 100 [%]
QtroponinT (168)/QHBDH (168) X 100 [%]
QHBDH (24)/QHBDH (72) X 100 [%]
QHBDH (10)/QHBDH (72) X 100 [%]
QCK (10)/QcK (72) X 100 [%]
QtroponinT (lOVQtroponinT (168) X 100 [%]
QtroponinT (5)/Qtropomn Τ (168) X 100 [%]
S+R+ = streptokinase treatment, reperfusion
S+R~ = streptokinase treatment, no reperfusion
S~ = no streptokinase treatment
2.23
61.4
12.0
21.3
12.9
2.04
5.23
5.32
0.21
0.36
6.6
6.1
66.7
35.7
30.4
22.2
14.9
+
±
+
·+·
+
+
+
+
+
-t-
+
+
-t-
+
+
±
·+·
1.32
11.3
3.4
6.0
3.8
0.85
2.89
4.90
0.16
0.27
3.3
2.9
16.9
16.8
14.3
18.5
25.9
CK =
HBDH =
S+R
7)
Mean ± SD
2.28
58.1
15.3
22.3
20.0
2.02
5.28
5.49
0.26
0.44
8.7
8.3
72.7
34.5
28.5
12.7
3.0
-i-
+
-t-
+
-1-
-»-
+
-1-
·+·
·+·
+
-t-
+
+
-t-
+
+
1.41
6.7
5.9
5.5
8.6
0.91
4.67
5.02
0.21
0.36
2.9
3.0
15.7
20.4
16.1
10.7
3.2
S~
(n = 7)
S+R+
vs S~ vs S~
S+R+
vs S+R~
Mean ± SD
2.21 ±
72.7 ±
19.7 ±
44.3 ±
24.0 ±
0.94 ±
6.44 ±
6.52 ±
0.22 ±
0.50 ±
8.6 ±
7.8 ±
55.7 ±
13.2 ±
19.7 ±
5.4 ±
3.2 ±
1.09
8.6
6.5
23.5
10.1
0.65
4.97
6.50
0.16
0.38
2.4
2.4
21.2
12.3
32.2
6.1
5.6
ns
ns
0.019
0.014
0.020
0.016
ns
ns
ns
ns
ns
ns
ns
0.018
0.052
0.008
ns
ns
0.015
ns
0.022
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
0.05
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
creatine kinase
ct-hydroxybutyrate dehydrogenase
10
50 100
Time after the onset of symptoms [h]
0 5 10
Time after the onset of symptoms [h]
Fig. 2a—c Mean cumulative release of troponin T (a), creatine
kinase (b) and hydrosybutyrate dehydrogenase (c) expressed in
g-eq/1 in patients treated with thrombolytic therapy, with reperfu-
sion (A, S+R+, n = 9) or without reperfusion (·, S+R~, n = 7)
and in patients not treated with thrombolytic therapy (o, S~,
n = 7). Upper standard error of the mean is indicated.
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Of course in studies on early prediction of vessel pat-
ency, 90 minutes angiography should be preferred to
judge the presence or absence of early reperfusion.
Troponin T and prediction of reperfusion
Clinical assessment of reperfusion following thrombo-
lytic therapy is an important feature for a clinician. As
a ^
Ο 5 10
Q HBDH at 72 hours [g-eq/l]
Fig. 3a—c Correlation between cumulative hydroxybutyrate de-
hydrogenase release at 72 hours and cumulative troponin Τ release
at 168 hours (a) and between hydroxybutyrate dehydrogenase and
cumulative creatine kinase release at 72 hours (b), expressed in
gram equivalents cardiac tissue per litre plasma in patients treated
with thrombolytic therapy, with reperfusion (A, S+R+, η = 9) or
without reperfusion (·, S+R~, η = 7) and in patients not treated
with thrombolytic therapy showing no reperfusion (o, S~, n = 7).
Fig. 3c presents the relation between (QtroponinT (168)/QHBDH (72))
X 100 and the cumulative hydroxybutyrate dehydrogenase release
at 72 hours for the different groups.
Regression lines:
fig. 3a:
A r = 0.92; y = 0.071x - 0.013
• r = 0.95; y = 0.063x + 0.109
O r = 0.96; y = 0.072x + 0.036
fig. 3b:
Ar = 0.93; y - 1.60x - 3.05
• r = 0.90; y = l.OSx - 0.05
O r = 0.86; y = 1.14x - 0.81
fig. 3c:
A r = 0.15; y = 0.177x + 5.6
• r = 0.19; y = 0.121x + 9.4
O r = 0.32; y = -0.273x + 10.4
a gold standard coronary angiography, performed ninety
minutes after the start of thrombolytic therapy, offers a
clear view of the status of the infarct-related vessel, but
is expensive, and may cause harm to the patient (5).
Clinical assessment of reperfusion on ECG-changes and
ventricular arrhythmias alone, however, is related with a
lower prognostic value, so the use of acute biochemical
markers is essential and has been the subject of many
investigations (7, 30). Troponin Τ has also been sug-
gested as a biochemical marker of reperfusion (6, 8, 12,
14). Katus et al. first showed the characteristic biphasic
plasma time-concentration curve for troponin T and in-
dicated that all patients with reperfusion < 5.5 h after
the onset of acute myocardial infarction had a ratio of
peak troponin T on day 1, to day 4 of > 1.0. The ratio
was < 1.0 in non-reperfused patients and in those with
reperfusion after 5.5 h (6).
Burlina et al. found 94% efficiency using the ratio of
serum troponin T at 16 h to serum troponin T at 32 h
after onset of chest pain. However, in this study most of
the non-reperfused patients were not treated with throm-
bolytic therapy and reperfusion was detected from clin-
ical symptoms and was confirmed angiographically only
in some cases (31).
Rempis et al. demonstrated that the probability of reper-
fusion was > 95% when the ratio of troponin T concen-
tration at 14 h over 38 h exceeded 1.09. They showed a
much better discriminating value of this ratio in patients
with reperfusion occurring within 4 hours after start of
treatment (12). We could confirm their results in non-
reperfused non-treated patients compared to reperfused
treated patients. In patients treated with thrombolytic
therapy, assessment of reperfusion from the troponin T
(16/36) ratio was not possible. This might be caused by
the fact that we determined vessel patency within 24
hours and not within 90 minutes. So, in our patients
reperfusion did not necessarily occur within 4 hours af-
ter start of treatment. This does not interfere with our
goal to compare the total amount of troponin T released
in the different patient groups.
For reliable prediction of thrombolysis from initial
slopes of cardiac markers, samples should be taken ev-
ery 15 minutes after start of treatment to estimate the
initial slope (8, 10, 14). Using early initial slopes of
serum markers to predict reperfusion Zabel et al. found
the best discriminating results using myoglobin. Com-
pared to troponin T or creatine kinase-MB mass initial
slopes, myoglobin showed earlier rise, yielding a better
negative predictive value and a higher area under the
ROC curve for non-invasive prediction of coronary ar-
tery patency after thrombolytic therapy (8). Abe et al.
found a comparable accuracy of 92% to predict reperfu-
sion from initial slope measurements for creatine kinase-
MB mass and troponin T. Initial slopes were obtained
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from 15 minutes samples during the first 90 minutes
(10). Laperche et al. showed that reliable early non-inva-
sive diagnosis of patency after thrombolysis from
plasma myoglobin or tropanin T is only possible in pa-
tients treated > 3 hours after onset of symptoms by use
of criteria derived from the relative increase over 90
minutes (14).
The aim of the present study was not to predict reperfu-
sion from plasma time activity or concentration curves,
but to investigate the cumulative release of troponin T,
as a percentage of cumulative cytosolic enzyme release,
in different patient groups. As troponin T is bound to
myofibrillar structures, presence or absence of reperfu-
sion might influence the cumulative release of this pro-
tein in a different way compared to the free cytosolic
enzymes; especially because it is known that cumulative
enzyme release, i. e. enzymatic infarct size, is not influ-
enced by vessel patency (29). Van der Laarse et al.
showed that the relation between enzymatic infarct size
assessed from cumulative hydroxybutyrate dehydroge-
nase release and left ventricular performance was not
influenced by the presence or absence of reperfusion
(29). As we studied cumulative release, plasma time-
concentration curves and cumulative release patterns
were indicated and calculated from the onset of symp-
toms and not from the onset of treatment. The latter is
only to be preferred in studies on prediction of reperfu-
sion from initial slopes.
Only few studies are available on the influence of reper-
fusion or treatment of thrombolytic therapy on cumula-
tive enzyme release, i. e., infarct size or release rate. In
a large scale study Van der Laarse et al. found that
thrombolysis in the early phase of acute myocardial in-
farction limits infarct size and that intra-coronary strep-
tokinase treatment itself positively influences the en-
zyme release rate, from the infarcted myocardium, inde-
pendent of treatment outcome determined angiographi-
cally (29). In the present study a comparable trend is
shown, although not significant. A larger study is neces-
sary to confirm these findings.
Recovery of the different markers
Quantitative recovery of cytosolic cardiac proteins into
plasma after ischaemic myocardial damage has been de-
monstrated in experimental studies. The total activities
of free cytosolic creatine kinase and hydroxybutyrate
dehydrogenase lost from dog heart after permanent cor-
onary occlusion (21) equalled the total release of these
proteins into plasma. These results cannot be directly
extrapolated to man. It was shown in the dog that protein
preparations infused into the infarcted myocardium
reach the circulation within a few hours (27). Such a
rapid washout of protein is effected by direct extravasa-
tion and flushing of the micro-vessels by the residual
blood flow in the infarcted area. In man, conditions
could be different and the washout period may be longer.
However, the fact that similar estimates of infarct size
are obtained for enzymes indicate that, also in man,
these cytoplasmic proteins are recovered completely in
plasma within 72—100 hours after the onset of symp-
toms (32, 33).
In a recent study we found that in patients receiving
thrombolytic therapy, cumulative troponin T release is
only a fraction of cumulative cytoplasmic creatine kinase
or hydroxybutyrate dehydrogenase release (19). Using a
total cardiac troponin T content of 234 g/g wet weight
the mean cumulative troponin T release after 168 hours
is about 8% of the cumulative release of cytoplasmic en-
zymes after 72 hours, when expressed in gram equiva-
lents normal cardiac tissue. So, for proteins bound to
myofibrillar structures there is no rapid washout, and
only the free circulating troponin T and the troponin T
released from the myofibrils after ischaemia reaches the
circulation. This is only a small fraction of the total
amount of troponin T present in cardiac tissue (19).
From the present study it became clear that cumulative
troponin T release is independent of treatment strategy or
outcome. Figure 3a shows that the correlation and slope
of cumulative hydroxybutyrate dehydrogenase versus tro-
ponin T release is not influenced by treatment strategy or
outcome. Moreover, the percentage of troponin T re-
leased is not influenced by infarct size (fig. 3c).
Troponin T for estimation of infarct size
Estimation of the extent of ischaemic myocardial injury
from the release of cytoplasmic cardiac enzymes into
plasma has become normal clinical practice and has
been applied successfully in the evaluation of the effect
of thrombolytic therapy after acute myocardial infarc-
tion (34, 32, 35). Several clinical studies have produced
convincing correlations between enzymatic and histo-
logic estimates of infarct size (26, 27, 36—39) or be-
tween enzymatic infarct size and infarct size estimated
from photon-emission computed tomography (40) or ra-
dionuclide estimates of myocardial infarct size (41).
We showed that although cumulative troponin T release
is only a fraction of the cumulative enzyme release,
there is a good correlation between cumulative cyto-
plasmic enzyme release (infarct size) and cumulative
troponin T release, independent of treatment strategy or
treatment outcome, vessel patency (fig. 3a—b).
Conclusions
— Creatine kinase and hydroxybutyrate dehydrogenase
release was completed within 72—100 hours in all pa-
tients, whereas troponin T release was still increasing
after 168 hours.
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— There was a significant difference in time to peak
value for cardiac enzymes and troponin T in patients
treated with thrombolytic therapy, showing reperfusion,
compared to those not treated with thrombolytic therapy
showing no reperfusion.
- Although plasma time-concentration curves of tro-
ponin T in patients treated with thrombolytic therapy
showing reperfusion, differed significantly from data of
patients not treated with thrombolytic therapy and show-
ing no reperfusion, after 168 hours the cumulative tro-
ponin T release was only 6—8% of the cardiac enzyme
release for all patients and is therefore not influenced by
the treatment strategy.
— Although cumulative troponin T release is only a
fraction of the cumulative enzyme release, there is a
good correlation between cumulative cytoplasmic en-
zyme release (infarct size) and cumulative troponin T
release, independent of treatment strategy or treatment
outcome, vessel patency.
— The rate of enzyme and troponin T release in patients
treated with streptokinase seems higher than the release
rate in patients not treated with streptokinase and with-
out spontaneous reperfusion. This could mean a direct
effect of the thrombolytic agent on the release rate of
troponin T. A more extensive study is necessary to con-
firm this finding.
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